Zobrazeno 1 - 10
of 173
pro vyhledávání: '"Oseledchyk A"'
Publikováno v:
Cancer Medicine, Vol 12, Iss 12, Pp 13388-13396 (2023)
Abstract Purpose Real‐world data about pegylated liposomal doxorubicin (PLD) in patients with metastatic breast cancer (MBC) are limited. We have aimed to highlight the role of PLD in daily practice focusing on older patients and patients with como
Externí odkaz:
https://doaj.org/article/10883d6fa71a4a53baab3fbb122d8220
Autor:
E.D. Chiru, C. Grasic Kuhar, A. Oseledchyk, A. Schötzau, M.J. Gonzalez, C. Kurzeder, M. Vetter
Publikováno v:
Translational Oncology, Vol 36, Iss , Pp 101724- (2023)
Background: In early luminal breast cancer, the Oncotype DX® Recurrence Score (RS) prognostic and predictive value with regards to chemotherapy (CHT) application benefit has been broadly validated. In older patients its value has not been deeply add
Externí odkaz:
https://doaj.org/article/929e7802051543bda43908d25b18983b
Autor:
Chiru, Elena Diana1,2 (AUTHOR) anton.oseledchyk@usb.ch, Oseledchyk, Anton1 (AUTHOR) marcus.vetter@ksbl.ch, Schoetzau, Andreas3 (AUTHOR) info@eudox.ch, Kurzeder, Christian4 (AUTHOR) christian.kurzeder@usb.ch, Mosimann, Raphael5 (AUTHOR) raphael.mosimann@stud.unibas.ch, Vetter, Marcus1,2,6 (AUTHOR) cgrasic@onko-i.si, Grašič Kuhar, Cvetka6,7,8 (AUTHOR)
Publikováno v:
Diagnostics (2075-4418). Jan2024, Vol. 14 Issue 1, p97. 15p.
Autor:
Wallrabenstein, Till1,2 (AUTHOR) marcus.vetter@ksbl.ch, Oseledchyk, Anton1 (AUTHOR), Daetwyler, Eveline1 (AUTHOR), Rochlitz, Christoph1 (AUTHOR), Vetter, Marcus1,3,4 (AUTHOR)
Publikováno v:
Cancers. Oct2023, Vol. 15 Issue 20, p4953. 10p.
Autor:
Elena Diana Chiru, Anton Oseledchyk, Andreas Schoetzau, Christian Kurzeder, Raphael Mosimann, Marcus Vetter, Cvetka Grašič Kuhar
Publikováno v:
Diagnostics, Vol 14, Iss 1, p 97 (2023)
In patients with hormone receptor positive, human epidermal receptor 2 negative (HR+/HER2−) negative breast cancer (BC), the TAILORx study showed the benefit of adding chemotherapy (CHT) to endocrine therapy (ET) in a subgroup of patients under 50
Externí odkaz:
https://doaj.org/article/47fddb00d3164bbc9d1dfbc8044ad8bf
Publikováno v:
healthbook TIMES. Oncology Hematology, Vol 11, Iss 1 (2022)
Over the past years, new systemic therapies for advanced and metastatic breast cancer have emerged, resulting in significantly improved survival outcomes in this patient population. This article provides a summary of selected clinically relevant stud
Externí odkaz:
https://doaj.org/article/3013aab9b0f1415cbe0a3ec868aafba1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Suchetan Pal, Angana Ray, Chrysafis Andreou, Yadong Zhou, Tatini Rakshit, Marek Wlodarczyk, Masatomo Maeda, Ricardo Toledo-Crow, Naxhije Berisha, Jiang Yang, Hsiao-Ting Hsu, Anton Oseledchyk, Jagannath Mondal, Shengli Zou, Moritz F. Kircher
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-13 (2019)
Currently available Raman scanners are limited in speed to acquire images of clinically relevant sizes in cancer imaging. Here, the authors developed a DNA based design principle for Raman-Fluorescence bimodal nanoparticles and demonstrate real-time,
Externí odkaz:
https://doaj.org/article/45b115ea90ac4c3fb323dba659f6adf6
Autor:
Ricca, Jacob M., Oseledchyk, Anton, Walther, Tyler, Liu, Cailian, Mangarin, Levi, Merghoub, Taha, Wolchok, Jedd D., Zamarin, Dmitriy
Publikováno v:
In Molecular Therapy 4 April 2018 26(4):1008-1019
Publikováno v:
Cancer Research. 83:P5-14
Introduction In early luminal HER2 negative breast cancer Oncotype DX® Recurrence-Score (RS) has been broadly validated in pre- and postmenopausal patients and can predict prognosis and benefit of chemotherapy. Its value in elderly breast cancer pop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b71188788e1245c03e55f414aa0d089
https://doi.org/10.1158/1538-7445.sabcs22-p5-14-13
https://doi.org/10.1158/1538-7445.sabcs22-p5-14-13